Search

Displaying results 1341 - 1350 of 1723 in total
  1. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    [L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]

  2. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah.

  3. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    [L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020.

  4. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: Nra-paroxetine
  5. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

  6. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.

  7. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  8. Drug

    alpha-Tocopherol acetate

    go.drugbank.com/drugs/DB14003
    Approved

    Alpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements. In particular, the RRR-alpha-tocopherol (or sometimes called the d-alpha-tocopherol stereoisomer) s...

    Mixtures: O-Cal FA multivitamin
  9. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]

  10. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    [L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518]